Sirolimus Conversion for Renal Dysfunction in Liver Transplant Recipients: The Devil Really Is in the Details…
Article first published online: 2 FEB 2012
© copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons
American Journal of Transplantation
Volume 12, Issue 3, pages 521–522, March 2012
How to Cite
McKenna, G. J. and Trotter, J. F. (2012), Sirolimus Conversion for Renal Dysfunction in Liver Transplant Recipients: The Devil Really Is in the Details…. American Journal of Transplantation, 12: 521–522. doi: 10.1111/j.1600-6143.2011.03922.x
- Issue published online: 28 FEB 2012
- Article first published online: 2 FEB 2012
- Received 28 September 2011, revised 02 November 2011 and accepted for publication 16 November 2011
- 1Information for Healthcare Professions: Sirolimus (marketed as Rapamune). Available at; http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/Drug-SafetyInformationforHeathcareProfessionals/ucm165015.htm. Accessed November 1, 2011.
- 5A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2007; 13: 1694–1702., , , et al.